1863
The risk of developing sAML is estimated to be between 1% and 5%, 2-20 years after exposure to etoposide but may also be related to cumulative drug doses, treatment schedules, host factors and co-administration of other antineoplastic agents.
 adverse event: after 
Please tell me event type and its trigger word from given type options. Output format is "type: trigger".  Option: adverse event, potential therapeutic event 
Text: {0} 
Answer:
 adverse event: after 